Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma ( mRCC ) in Australia-Reference-Cited by-同舟云学术

Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma ( mRCC ) in Australia

Published:2021-07 Issue:7 Volume:51 Page:1173-1177
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Balasubramanian Adithya¹²,Qu Liang³,Weickhardt Andrew¹,Bolton Damien³,Perera Marlon³⁴^ORCID

Affiliation:

1. Olivia Newton‐John Cancer Wellness and Research Centre, Austin Health Melbourne Victoria Australia

2. Department of Medical Oncology Monash Health Melbourne Victoria Australia

3. Department of Surgery, Austin Health University of Melbourne Melbourne Australia

4. Department of Urology, Western Health University of Melbourne Victoria Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15419

Reference20 articles.

1. Cancer Australia Australian Government. Kidney cancer. Kidney cancer in Australia statistics. Sydney: Cancer Australia;2020. Available fromhttps://kidney-cancer.canceraustralia.gov.au/statistics

2. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data

3. Services Australia Australian Government. Pharmaceutical Benefits Schedule item reports: Medicare statistics. Canberra: Services Australia;2020. Available fromhttp://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp

4. Australian Bureau of Statistics (ABS). Canberra: Australian Government;2020. Available fromhttps://www.abs.gov.au/AUSSTATS

5. Overall survival and independent review of response in CheckMate 214 with 42‐month follow‐up: first‐line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC);Tannir NM;J Clin Oncol,2020